CA3231124A1 - Antibodies targeting ccr2 - Google Patents

Antibodies targeting ccr2 Download PDF

Info

Publication number
CA3231124A1
CA3231124A1 CA3231124A CA3231124A CA3231124A1 CA 3231124 A1 CA3231124 A1 CA 3231124A1 CA 3231124 A CA3231124 A CA 3231124A CA 3231124 A CA3231124 A CA 3231124A CA 3231124 A1 CA3231124 A1 CA 3231124A1
Authority
CA
Canada
Prior art keywords
antibody
seq
ccr2
human
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231124A
Other languages
English (en)
French (fr)
Inventor
Matthias Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Granite Bio Ag
Original Assignee
Granite Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Granite Bio Ag filed Critical Granite Bio Ag
Publication of CA3231124A1 publication Critical patent/CA3231124A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3231124A 2021-10-27 2022-10-25 Antibodies targeting ccr2 Pending CA3231124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204904 2021-10-27
EP21204904.3 2021-10-27
PCT/EP2022/079744 WO2023072916A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Publications (1)

Publication Number Publication Date
CA3231124A1 true CA3231124A1 (en) 2023-05-04

Family

ID=78413745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231124A Pending CA3231124A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Country Status (10)

Country Link
US (2) US12168692B1 (https=)
EP (1) EP4423131A1 (https=)
JP (1) JP2024540196A (https=)
KR (1) KR20240099211A9 (https=)
CN (1) CN118159562A (https=)
AU (1) AU2022378899A1 (https=)
CA (1) CA3231124A1 (https=)
IL (1) IL311476A (https=)
MX (1) MX2024004447A (https=)
WO (1) WO2023072916A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245988A1 (en) * 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2016079276A1 (en) 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease

Also Published As

Publication number Publication date
US20240392018A1 (en) 2024-11-28
AU2022378899A1 (en) 2024-03-07
MX2024004447A (es) 2024-05-08
KR20240099211A (ko) 2024-06-28
US12168692B1 (en) 2024-12-17
CN118159562A (zh) 2024-06-07
JP2024540196A (ja) 2024-10-31
WO2023072916A1 (en) 2023-05-04
KR20240099211A9 (ko) 2025-12-10
EP4423131A1 (en) 2024-09-04
IL311476A (en) 2024-05-01
US20250059288A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
CN112912397B (zh) 抗cd3抗体及其用途
CN116041516A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
WO2022105914A1 (zh) Cd70抗体及其应用
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
JP2024531462A (ja) Ｆａｐ／ｃｄ４０結合分子及びその医薬的使用
JP7717687B2 (ja) 腎疾患における抗幹細胞因子抗体及びその使用方法
US20250059288A1 (en) Antibodies targeting ccr2
US20250382362A1 (en) Antibodies targeting il3
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
WO2024245988A1 (en) Antibodies targeting ccr2
HK40111251A (zh) 靶向ccr2的抗体
US12304958B2 (en) Antibodies targeting ActRIIA and ActRIIB
WO2024213046A1 (en) Anti-cd25 antibody and uses thereof
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
TW202317626A (zh) 抗il-36r抗體及其用途
EA045935B1 (ru) Антитела к cd3 и их применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015